Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.
Ms. Jenni Pilcher es el Chief Executive Officer de Cann Group Ltd, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción CNGGF?
El precio actual de CNGGF es de $0.0063, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Cann Group Ltd?
Cann Group Ltd pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Cann Group Ltd?
La capitalización bursátil actual de Cann Group Ltd es $10.0M
¿Es Cann Group Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Cann Group Ltd, incluyendo 1 fuerte compra, 3 compra, 1 mantener, 0 venta, y 1 fuerte venta